First International Inflammatory Breast Cancer Conference

第一届国际炎症性乳腺癌会议

• 批准号: 7614068
• 负责人: Massimo Cristofanilli
• 金额: $ 0.65万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-08 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7614068
• 关键词: Advocacy; Advocate; African American; Angiogenic Factor; Attention; Awareness; Breast Diseases; Clinical; Clinical Management; Clinical Trials; Communities; Consultations; Counseling; Country; Data; Development; Disease; Disease Management; Education; Ensure; Epidermal Growth Factor Receptor; Faculty; Focal Infection; Goals; Health Professional; Individual; Inflammatory; International; Invasive; Investigation; Knowledge; Malignant Neoplasms; Medical; Mind; Molecular; NIH Program Announcements; Nature; Nurses; Participant; Patient Care; Patient Care Management; Patients; Phase; Physicians; Practice Guidelines; Prevalence; Protein Overexpression; Provider; Public Health; Range; Reporting; Research; Research Personnel; Scientist; Thinking; Training; Update; Visit; Woman; clinical Diagnosis; design; health disparity; interest; malignant breast neoplasm; mastitis; programs; symposium

DESCRIPTION (provided by applicant): Inflammatory breast cancer (IBC) is a rare, but aggressive, invasive and often deadly form of breast disease. IBC is often identified as a localized infection, i.e. mastitis, delaying proper treatment and resulting in rapid progression. In addition to diagnosis, the clinical and molecular understandings of IBC remain unclear. Its uncommon nature and vague management necessitate a forum in which experts and investigators in the field may present the most up to date information regarding IBC. The First International Conference on Inflammatory Breast Cancer seeks to educate and inform its participants, in order to bring about awareness and collective knowledge into clinical diagnosis, disease management, and molecular investigation. Our meeting will draw international faculty and participants from many countries. For example, seven of our speakers will represent five different countries, and we expect a high turn out from visiting scientists and physicians. We are targeting a diverse audience in order to educate faculty, physicians, mid-level providers, nurses, trainees and patient/advocates with up-to-date material ranging from clinical presentation and molecular mechanisms to health disparities and patient counseling. Our sessions are designed with this wide range of audience in mind and include breakout sessions for individual levels of development. With recent attention to IBC through the media and advocacy programs, our first of its kind symposium comes at a timely manner when interest is high. Program Goals We are designing this conference to educate faculty, physicians, mid-level providers, nurses as well as trainees at all levels. Together with international thought-leaders of inflammatory breast cancer (IBC) in both research and clinical management, attendees will have the opportunity to gather knowledge about successfully identifying and treating the rare nature of this disease. With our focus on training everyone from patient advocates to physicians, we plan to successfully raise awareness and promote the sharing of accurate information regarding IBC. The rare nature and unique presentation of IBC demands a re-education of health care professionals in order to ensure that misdiagnoses are eliminated and patient care is enhanced. In addition to communicating medical guidelines and practice regarding IBC, we will also focus on the latest research seeking to elucidate the molecular mechanisms that drive IBC initiation and progression, along with an update of clinical trials' data (i.e. Phase I reports of agent tolerability, EGFR overexpression, angiogenic factors, osteopenia) and epidemiological data, ex. demonstrating the increased prevalence in African American women communities. It is our goal that long standing relationships will be formed allowing for networking and consultation in the international cancer community promoting effective and efficient treatment and management. Each section of our symposium was designed with patient benefit in mind, including a patient/advocate breakout session that will enrich patient knowledge and offer support. Through education, management and therapy of those connected to and impacted by IBC, we hope to eliminate any delay in the assessment of IBC, thus allowing optimum patient care and management and stimulating the search for curative therapies. Public Health Relevance: A Project Narrative was not included in the Program Announcement PA-06-041 and therefore assumed not required for this submission. For project details please see "Conference Plan".

描述（由申请人提供）：炎性乳腺癌（IBC）是一种罕见的，但侵略性，侵入性和往往致命的乳腺疾病。IBC通常被鉴定为局部感染，即乳腺炎，延迟适当的治疗并导致快速进展。除了诊断，IBC的临床和分子认识仍然不清楚。国际生物伦理委员会的特殊性和管理的模糊性要求有必要设立一个论坛，让该领域的专家和调查人员介绍有关国际生物伦理委员会的最新信息。第一届国际炎症性乳腺癌会议旨在教育和告知其参与者，以便将意识和集体知识带入临床诊断，疾病管理和分子研究。我们的会议将吸引来自许多国家的国际教师和参与者。例如，我们的七位演讲者将代表五个不同的国家，我们预计来访的科学家和医生会有很高的出席率。我们针对不同的受众，以教育教师，医生，中级供应商，护士，受训人员和患者/倡导者，提供最新的材料，从临床表现和分子机制到健康差异和患者咨询。我们的课程设计考虑到了这一广泛的受众，并包括针对个人发展水平的分组会议。随着最近通过媒体和宣传计划对IBC的关注，我们的第一次此类研讨会在兴趣高涨时及时举行。 计划目标我们正在设计这次会议，以教育教师，医生，中级供应商，护士以及各级学员。与炎症性乳腺癌（IBC）研究和临床管理方面的国际思想领袖一起，与会者将有机会收集有关成功识别和治疗这种疾病罕见性质的知识。我们专注于培训从患者倡导者到医生的每个人，我们计划成功地提高人们对IBC的认识，并促进有关IBC的准确信息的共享。IBC的罕见性和独特表现要求对卫生保健专业人员进行再教育，以确保消除误诊并加强患者护理。除了交流有关IBC的医学指南和实践外，我们还将关注最新的研究，以阐明驱动IBC发生和进展的分子机制，沿着更新的临床试验数据（即药物耐受性，EGFR过表达，血管生成因子，骨质减少的I期报告）和流行病学数据，例如。这表明非裔美国妇女社区的患病率有所上升。我们的目标是建立长期的关系，以便在国际癌症社区建立网络和进行咨询，促进有效和高效的治疗和管理。我们研讨会的每一部分都是在考虑患者利益的情况下设计的，包括一个患者/倡导者分组会议，这将丰富患者的知识并提供支持。通过对那些与IBC相关并受其影响的人进行教育，管理和治疗，我们希望消除IBC评估中的任何延迟，从而实现最佳的患者护理和管理，并刺激对治愈性疗法的探索。 公共卫生相关性：项目叙述未包含在项目公告PA-06-041中，因此认为本次提交不需要。有关项目详情，请参阅“会议计划”。